Malnutrition in older adults remains under-recognized across healthcare settings despite advances in digital screening and monitoring technologies. Recent evidence highlights the potential of digital tools to improve nutritional risk identification, but their translation into effective clinical interventions remains insufficiently established. This commentary builds on the recent review by Amatrudo et al. to critically examine the transition from technology-assisted malnutrition detection to equitable, clinically actionable nutrition-care pathways. Digital screening systems should be evaluated beyond diagnostic accuracy and operational efficiency. Important priorities include external validation across diverse populations, integration with dietitian-led interventions, age-friendly and multilingual interfaces, caregiver participation, algorithmic fairness, and human oversight. We propose a four-component validation pathway encompassing population-level validation, integration of screening with nutritional interventions, equitable digital implementation, and evaluation of patient-centred outcomes, including functional decline, hospitalization, quality of life, and cost-effectiveness. The future of digital malnutrition care requires a shift from identifying nutritional risk to delivering timely, accountable, and equitable interventions. This commentary advocates globally adaptable, clinically integrated digital nutrition systems that prioritize measurable patient benefit.
This scoping review aims to present the scientific literature on the associations of climate events (extreme weather events and climate variability) with anthropometric outcomes, food security, and the food environment. It aims to map evidence, analyze the existing findings, identify gaps, and improve the understanding of how climate events are associated with these outcomes, offering insights into the development of intersectoral actions in the face of the emerging risks of the climate crisis. From the 78 included studies (47.4
Parkinson’s Disease (PD) is a progressive neurodegenerative disorder characterized by motor and nonmotor symptoms due to dopaminergic neuron degeneration. Recently, there has been growing interest in the impact of different dietary patterns on PD management. This review aims to evaluate the potential benefits and risks of the Mediterranean diet, ketogenic diet, and MIND diet in improving PD symptoms and disease progression. The Mediterranean diet, rich in antioxidants and anti-inflammatory components, may help alleviate PD symptoms and slow disease progression. The ketogenic diet has shown promise in improving motor symptoms through the neuroprotective effects of ketone bodies. The MIND diet, known for its cognitive health benefits, may help mitigate cognitive decline in PD patients. However, studies directly assessing the efficacy of these diets in PD are still limited. A balanced diet plays a crucial role in managing PD symptoms and enhancing the quality of life. While current evidence suggests potential benefits of specific dietary patterns, further large-scale and long-term studies are necessary to determine their direct effects on PD progression and symptom management.
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline associated with oxidative stress, neuroinflammation, tau neurofibrillary tangles, amyloid-beta plaque deposition, and metabolic dysfunction. Increasing evidence suggests that the gut microbiota plays an important role in AD pathogenesis through the microbiota–gut–brain axis. This review aims to provide a comprehensive overview of the role of the gut microbiota in AD and healthy aging, with a particular focus on microbiota-targeted preventive and therapeutic strategies and their potential to influence disease progression. Recent studies have demonstrated that alterations in gut microbial composition are closely associated with AD. Patients with AD commonly exhibit a reduced abundance of short-chain fatty acid–producing bacteria and an increased prevalence of lipopolysaccharide-producing taxa, supporting a mechanistic link between microbial dysbiosis, systemic inflammation, and neurodegeneration. Emerging evidence indicates that dietary patterns, prebiotics, probiotics, synbiotics, postbiotics, and microbiota-based therapies, including fecal microbiota transplantation (FMT), may beneficially modulate gut microbial composition and influence AD-related pathophysiological processes. In addition, lifestyle factors such as sleep quality and physical activity have been increasingly recognized for their interactions with the gut–brain axis and their potential to affect cognitive health. Current evidence highlights the gut microbiota as a promising therapeutic target in AD prevention and management. Microbiota-directed interventions, together with healthy dietary and lifestyle modifications, may help attenuate neuroinflammation, improve metabolic homeostasis, and delay cognitive decline. Furthermore, given the substantial global economic burden of AD, microbiota-focused preventive strategies may contribute not only to improving clinical outcomes but also to reducing long-term healthcare and societal costs. Future longitudinal and interventional studies are needed to establish causal relationships and determine the efficacy of microbiota-based therapies in AD.
This systematic review evaluates the association between nut consumption and kidney health outcomes, including kidney function markers and chronic kidney disease (CKD) incidence, prevalence, and mortality. Given the nutritional benefits of nuts and the growing burden of CKD, we aimed to assess whether nut consumption is associated with kidney-related outcomes and to assess the strength and consistency of the available evidence. Recent observational studies and cohort analyses provide emerging but heterogeneous evidence on the relationship between nut intake and kidney outcomes. Higher nut consumption and substitution of red and processed meat with nuts are associated with lower CKD risk or prevalence in some populations. However, findings for specific kidney function markers, such as estimated glomerular filtration rate and albuminuria, remain inconsistent across studies. Nuts have also been evaluated within plant-based dietary indices and through biomarker-based approaches, yielding complementary but non-uniform results. Evidence in individuals with established CKD or high-risk populations is limited. Overall, variability in exposure definitions, outcome measures, and study populations contributes to uncertainty in the strength and consistency of associations. Current evidence suggests that nut consumption, particularly when nuts replace red and processed meat, may be associated with favorable kidney-related outcomes in some populations. However, the evidence is predominantly observational and does not establish causality or an optimal level of nut consumption for kidney health. The heterogeneity in study design and outcome assessment further constrains definitive conclusions. Future research should prioritize well-designed prospective studies and randomized controlled trials to establish causality, clarify dose–response relationships, and determine the role of nuts in CKD-specific dietary recommendations for its prevention and management.
